°øÁö»çÇ×

HOME > ÇÐȸ¼Ò°³   >   °øÁö»çÇ×

±Þ¼º °ñ¼ö¼º¹éÇ÷º´/°ñ¼öÇü¼ºÀÌ»óÁõÈıº ¿¬±¸È¸ ½ÉÆ÷Áö¿ò °³ÃÖ ¾È³»
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
ÀÛ¼ºÀÏ
2006-08-09
Á¶È¸
6727
¾È³çÇϽʴϱî?

´ëÇÑÇ÷¾×ÇÐȸ ±Þ¼º °ñ¼ö¼º¹éÇ÷º´/°ñ¼öÇü¼ºÀÌ»óÁõÈıº (AML/MDS) ¿¬±¸È¸¿¡¼­´Â 2006³âµµ »ç¾÷°èȹÀÇ ÀÏȯÀ¸·Î µÎ¹ø° ½ÉÆ÷Áö¾öÀ» 9¿ù 9ÀÏ(Åä) ¿ÀÈÄ ´ëÀü Ãæ³²´ëº´¿ø¿¡¼­ °³ÃÖÇÒ ¿¹Á¤¿¡ ÀÖ½À´Ï´Ù. ±Ý¹ø ½ÉÆ÷Áö¾öÀº "The Art of Diagnosis and Treatment of Myelodysplastic Syndrome"À̶ó´Â Á¦¸ñÀ¸·Î ÁøÇàµÇ°ÚÀ¸¸ç, ¸ðµÎ 10 ºÐÀÇ ¿¬ÀÚ¸¦ ¸ð½Ã°í MDS¿¡¼­ÀÇ º´Å»ý¸®, Áø´Ü, Ä¡·á¿¡¼­ÀÇ ÃֽŠÁö°ßÀ» Á¾ÇÕÀûÀ¸·Î ¹ßÇ¥ÇÏ°í, ¼­·ÎÀÇ °æÇè°ú ÀÇ°ßÀ» ³ª´©´Â ¼ÒÁßÇÑ ÀÚ¸®·Î ÁغñÇÒ ¿¹Á¤¿¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ AML/MDS ¿¬±¸È¸ ´Ù±â°ü °øµ¿¿¬±¸ÀÇ ÁøÇà »çÇ×µµ º¸°í µå¸®°í, »õ·Î¿î ¿¬±¸°èȹ¿¡ ´ëÇÑ ¼Ò°³µµ µå¸®´Â ÀÚ¸®¸¦ À̾ °®°Ú½À´Ï´Ù.

ÁÖÁöÇÏ´Ù½ÃÇÇ MDS¿¡¼­´Â ÃÖ±Ù »õ·Î¿î ¾àÁ¦µéÀÌ °³¹ßµÇ¾î Ä¡·á¿¡ »ç¿ëµÇ±â ½ÃÀÛÇÏ¿´À¸¸ç, µû¶ó¼­ Á¤ÇÐÇÑ Áø´Ü°ú ¿¹ÈÄ¿¹ÃøÀ» ÅëÇØ È¿°úÀûÀÎ Ä¡·á¹æħÀ» Àç Á¤¸³ÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ±Ý¹ø ½ÉÆ÷Áö¾öÀ» ÅëÇØ MDS¿¡ ´ëÇÑ ±¹³» Àü¹®°¡µéÀÇ Çй®ÀûÀÎ consensus°¡ Á¶¼ºµÇ°í, ³ª¾Æ°¡ Áø´Ü ¹× Ä¡·á Ãø¸é¿¡¼­ È¿°úÀûÀÎ Korean GuidelineÀÌ Á¤¸³µÇ¾î, ±¹³» Ç÷¾×ÇÐÀÇ globalization¿¡ Å©°Ô ±â¿©ÇÏ´Â ±âȸ°¡ µÉ ¼ö Àֱ⸦ ±â´ëÇÕ´Ï´Ù. ȸ¿ø ¿©·¯ºÐÀÇ ¸¹Àº Âü¼®À» ±â´ëÇÕ´Ï´Ù.

¿¬±¸È¸ À§¿øȸ ¹Î À¯ È«


The Art of Diagnosis and Treatment of Myelodysplastic Syndrome

ÀϽà : 2006. 9¿ù 9ÀÏ (Åä) 12:00-17:30
Àå¼Ò : Ãæ³²´ëº´¿ø ÀÀ±ÞÀÇ·á¼¾ÅÍ ÀÇÇàȦ

Program

12:00-12:50 µî·Ï ¹× Á¢¼ö
* °£´ÜÇÑ ½º³¼ÀÌ ÁغñµË´Ï´Ù

12:50-13:00 °³È¸»ç, Ãà»ç

13:00-13:20 Molecular & Biological Pathophysiology in MDS
¼øõÇâÀÇ´ë ³»°ú ¿øÁ¾È£

13:25-13:45 Current status of MDS diagnosis in Korea
¿¬¼¼ÀÇ´ë ³»°ú Á¤ÁØ¿ø

13:50-14:10 Frequently encountered diagnostic challenges in MDS
¼º±Õ°üÀÇ´ë Áø´Ü°Ë»çÀÇÇаú ±è¼±Èñ

14:15-14:35 Unusual clinical problems encountered in MDS
µ¿¾ÆÀÇ´ë ³»°ú ±è¼ºÇö

14:40-15:00 How do we treat low-risk MDS patients?
¼º±Õ°üÀÇ´ë ³»°ú ¾ÈÁø¼®

15:05-15:30 Coffee break

15:30-15:50 How do we treat high-risk MDS patients?
Ãæ³²ÀÇ´ë ³»°ú Á¶´ö¿¬

15:55-16:15 Transplantation strategy in MDS
¼­¿ïÀÇ´ë ³»°ú À±¼º¼ö

16:20-16:40 MDS in childhood
Àü³²ÀÇ´ë ¼Ò¾Æ°ú ±¹ÈÆ

16:45-17:05 Novel therapeutic agents in the treatment of MDS
°Ç±¹ÀÇ´ë ³»°ú ÀÌÈ«±â

17:10-17:30 KSH AML/MDS WP Multi-center Clinical trials
¿¬¼¼ÀÇ´ë ³»°ú ¹ÎÀ¯È«

17:30 Closing